INDV · Indivior Pharmaceuticals, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $350M | Six Months Ended June 30, 2026 | — |
| New patient starts | 32,816 | Q2 2026 | — |
|
|
|||
| Non-GAAP net income non-GAAP | $266M | Six Months Ended June 30, 2026 | — |
| Patients prescribed SUBLOCADE since launch (cumulative) | 545,000 | as of June 30, 2026 | — |
| U.S. SUBLOCADE dispense unit volume growth | 18% | Q2 2026 | — |
|
|
|||
| Total SUBLOCADE Net Revenue | 232M | Q1 2026 | — |
| SUBLOCADE dispense unit volume growth | 7% | FY 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INDV
this stock
Indivior Pharmaceuticals, Inc.
|
$4.60B | +8.7% | +4.3% | 14.0 | 9.2% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$56.30B | +13.1% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.59B | +2.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$42.85B | +17.8% | +4.3% | 60.3 | 2.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INDV | +0.5% | -3.8% | +18.5% | -2.5% | +8.7% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | +0.1% | -8.2% | +4.7% | -6.4% | -5.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.